Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof
21.7.2022 18:00:00 EEST | Business Wire | Press release
Innovaderm’s involvement in all phases of the clinical development of tapinarof culminated with a tremendous achievement: the recent approval of Dermavant Sciences’ VTAMA® (tapinarof) cream by the FDA for the treatment of plaque psoriasis in adults.
Discovered in Canada, tapinarof is approved in the United States for the management of psoriasis, a chronic skin condition that causes itchy, scaly patches on different parts of the body and has a significant detrimental effect on quality of life.
“This is a great milestone for patients – one that we have been working towards for years,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis. We not only played an instrumental role through our participation in multicenter phase 2 and 3 studies, but we were also the first to demonstrate tapinarof’s efficacy in proof-of-concept studies in both psoriasis and atopic dermatitis.”
VTAMA® cream is a once-daily, topical medication for psoriasis. Currently, clinical trials are underway to study this medication among patients with atopic dermatitis.
“VTAMA® cream is a non-steroidal topical that is a new chemical entity and the first-in-class therapy to be approved in the topical psoriasis space in 25 years,” says Anna Tallman, PharmaD, Vice-President of Medical Affairs at Dermavant Sciences. “We appreciate the collaboration and partnership with Dr. Bissonnette and Innovaderm to help bring forward an effective new treatment option in the United States that has the potential to benefit adults with plaque psoriasis across the entire disease severity spectrum – from mild to severe.”
Dr. Bissonnette and Tallman recently contributed to an article on the phase 3 tapinarof studies, which was published in the New England Journal of Medicine. To learn more: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2103629
For information on Innovaderm’s early to late phase study capabilities, visit our website.
IMPORTANT SAFETY INFORMATION
Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist approved in the US for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
See full Prescribing Information and Patient Information.
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
Dermavant Sciences
Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company’s medical dermatology pipeline includes both approved and late-stage development product candidates the company believes may address important immuno-dermatological conditions, including plaque psoriasis and atopic dermatitis. For more information, please visit www.dermavant.com, and follow us on Twitter (@dermavant) and LinkedIn (Dermavant Sciences).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005175/en/
Contact information
For more information:
Kathy Giangaspero
Communications Specialist
Innovaderm Research Inc.
kgiangaspero@innovaderm.com
Anna Tallman
Vice-President, Medical Affairs
Dermavant Sciences
anna.tallman@dermavant.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infopro Digital Automotive Highlights Its Industry-Leading Datasets at Automechanika 202626.8.2026 11:02:00 EEST | Press release
Infopro Digital Automotive, leader in data and software for the automotive market, announces its participation in Automechanika 2026, the world’s leading trade fair for the automotive industry. After completing several significant acquisitions over the past years, including Eucon, GiPA, and Aurelis last September, the company will attend this year’s trade show with a consolidated offering, built upon its trusted industry-leading datasets. Infopro Digital Automotive now addresses every automotive vertical from independent workshops to parts, tyres and car manufacturers, through the whole network of aftermarket distribution professionals, thus delivering to them key data and integrated digital solutions to power strategic decisions at every step of the vehicle lifecycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826133342/en/ Infopro Digital Automotive’s unmatched dataset portfolio will be presented at Automechanika 20
NIPPON KINZOKU Establishes Mass Production of Ultra-Thin and Narrow Stainless Steel for Insulin Needles26.8.2026 11:01:00 EEST | Press release
NIPPON KINZOKU CO., LTD. (Headquarters: Minato-ku, Tokyo; President: Yasushi Shimokawa; TOKYO: 5491) is pleased to announce the commencement of mass production for its "Ultra-thin and narrow-width stainless steel" optimized for laser welding in ultra-fine insulin needles. In response to growing global demand, the company has established a stable supply system for these high-quality materials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826770424/en/ The scale of the global diabetes crisis is expanding. In line with this trend, the global demand for insulin needles continues to escalate. Furthermore, insulin delivery is evolving toward "painless" experiences that reduce patient burden. Modern designs prioritize minimizing pain and bruising, leading to the widespread adoption of ultra-fine needles. This trend is further supported by the growing popularity of compact, portable pen injectors. Additionally, the global rise
VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data26.8.2026 11:00:00 EEST | Press release
VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1 clinical trial. VirTus has worked on the APL-10456 programme for more than five years, conducting more than 20 preclinical studies to support the selection, development and progression of the candidate, testing the cross-species immunogenicity and efficacy. This work included evaluating the efficacy of several vaccine candidates in mouse models of rhinovirus infection, helping to select APL-10456 and establish early proof of concept and generating preclinical evidence that informed its progression into first-in-human clinical development. APL-10456 is a first-in-class, adjuvanted recombinant protein subunit
Xsolla President Chris Hewish Debuts “Durable Advantage” at Gamescom 202626.8.2026 10:00:00 EEST | Press release
Xsolla, a leading global commerce company, today announced Durable Advantage: Five Pillars of the Modern Game Business, a new book authored by Chris Hewish, President of Xsolla, launching at Gamescom 2026 in Cologne. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826628682/en/ Graphic: Xsolla Xsolla's integrated strategy brings together global payments, direct-to-consumer commerce, backend infrastructure, and AI-powered development tools into a unified operating model designed to help studios launch, operate, and scale more efficiently. Rather than relying on disconnected commerce, engagement, and backend systems, developers can activate new capabilities through a common platform foundation that reduces complexity, accelerates deployment, and creates a more durable foundation for long-term growth. The strategic framework behind this vision is outlined in Durable Advantage. "There are two kinds of game companies, renters a
David Hagan, Dean and Pegasus Professor at CREOL, The College of Optics and Photonics, Will Serve as Vice President of SPIE26.8.2026 06:00:00 EEST | Press release
David Hagan has been elected to serve as the 2027 Vice President of SPIE, the international society for optics and photonics. He will serve as President-Elect in 2028, and as the Society’s President in 2029. The SPIE Board of Directors is influential in the scientific community, establishing policy and strategy and conducting activities of interest to SPIE Members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825934622/en/ Top row, from left to right: David Hagan, Jim McNally, Mark Clampin. Bottom row, from left to right: Marla Dowell, Jana Kainerstorfer, Katie Schwertz The 2026 SPIE President, Julie Bentley, professor of optics at the University of Rochester, made the new electees announcement at the Annual General Meeting of the Society on 25 August during SPIE Optics + Photonics. Terms begin on 1 January 2027. In addition to his work at CREOL (University of Florida, USA), Hagan has been an SPIE Fellow since 2017.His
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom